Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2007 2
2008 3
2009 5
2010 11
2011 9
2012 6
2013 6
2014 10
2015 12
2016 5
2017 12
2018 14
2019 8
2020 14
2021 20
2022 11
2023 11
2024 16
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Agarwal R, et al. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. N Engl J Med. 2025. PMID: 40470996 Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Kanwal F, et al. Among authors: shubrook jh. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20. Gastroenterology. 2021. PMID: 34602251 Free PMC article. Review.
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, Eguchi Y, Castera L, Pessoa MG, Oliveira CP, El-Kassas M, Tsochatzis E, Fan JG, Spearman CW, Tacke F, Castellanos Fernandez MI, Alkhouri N, Schattenberg JM, Romero-Gómez M, Noureddin M, Allen AM, Ong JP, Roberts SK, Shubrook JH, Burra P, Kohli R, Kautz A, Holleboom AG, Lam B, Isaacs S, Macedo P, Gastaldelli A, Henry L, Ivancovsky-Wajcman D, Nader F, de Avila L, Price JK, Mark HE, Villota-Rivas M, Barberá A, Kalligeros M, Gerber LH, Alqahtani SA. Younossi ZM, et al. Among authors: shubrook jh. Gastroenterology. 2025 Oct;169(5):1017-1032.e2. doi: 10.1053/j.gastro.2025.02.044. Epub 2025 Apr 11. Gastroenterology. 2025. PMID: 40222485 Free article.
Pharmacology-Insulin.
Shubrook JH, Pfotenhauer KM. Shubrook JH, et al. Prim Care. 2022 Jun;49(2):301-313. doi: 10.1016/j.pop.2021.11.013. Epub 2022 Apr 27. Prim Care. 2022. PMID: 35595484 Review.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.
Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, Bardsley JK, Beverly EA, Corbin KD, ElSayed NA, Isaacs S, Kanwal F, Pekas EJ, Richardson CR, Roden M, Sanyal AJ, Shubrook JH, Younossi ZM, Bajaj M. Cusi K, et al. Among authors: shubrook jh. Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094. Diabetes Care. 2025. PMID: 40434108 Review.
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. Agarwal R, et al. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022. Nephrol Dial Transplant. 2025. PMID: 39916475 Free PMC article. Clinical Trial.
178 results